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Abstract
Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. In
order to better understand the genetic etiology of osteosarcoma, we performed a multi-stage
genome-wide association study (GWAS) consisting of 941 cases and 3,291 cancer-free adult
controls of European ancestry. Two loci achieved genome-wide significance: rs1906953 at
6p21.3, in the glutamate receptor metabotropic 4 [GRM4] gene (P = 8.1 ×10-9), and rs7591996
and rs10208273 in a gene desert on 2p25.2 (P = 1.0 ×10-8 and 2.9 ×10-7). These two susceptibility
loci warrant further exploration to uncover the biological mechanisms underlying susceptibility to
osteosarcoma.
Main Text
Osteosarcoma is the most common primary malignant bone tumor in children and young
adults, affecting approximately four persons per million per year in the U.S.1. The peak
incidence correlates with the pubertal growth spurt, occurring earlier in females than in
males. It is more common at sites of rapid bone growth. Tall stature and high birth weight
are proven risk factors2, and osteosarcoma is a syndrome-associated malignancy in the Li-
Fraumeni syndrome, Rothmund-Thomson syndrome, and hereditary retinoblastoma cancer
susceptibility syndromes. Several small case-control studies have reported preliminary
associations of common genetic variants with osteosarcoma risk in biologically-plausible
pathways 3-11, e.g., growth and DNA repair, but statistical power has been limited by small
sample sizes12.
We developed an international, multi-institutional collaborative study of osteosarcoma to
conduct a GWAS (Supplementary Table 1). Germline genomic DNA was extracted from
either blood or buccal cells drawn from osteosarcoma case series using standard methods.
Participating subjects provided informed consent under the auspices of local Institutional
Review Boards. Control subjects were selected from previously-scanned cancer-free adults
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over the age of 55 years drawn from large case control and cohort studies as per an approach
successfully used for Ewing sarcoma13 and pediatric acute lymphoblastic leukemia (ALL)14.
Genotyping of all cases was conducted using the Illumina OmniExpress SNP microarray
over time resulting in two parts, known as Stage 1A and 1B, due to the staggered receipt of
samples in this multi-institutional study design (Supplementary Figure 1, Online Methods).
Stage 1A genotyped 910 available osteosarcoma cases from five studies. Based on quality
control filtering (including locus or sample missing rates, sample heterozygosity, Hardy-
Weinberg equilibrium, and sex verification) and assessment of underlying population
substructure (STRUCTURE and principal components analyses), 596 cases of European
ancestry were advanced to the primary GWAS analysis (Supplementary Figures 2 and 3); 97
African American and 99 Hispanic cases were identified and excluded from the present
analysis. A later download of samples, known as Stage 1B consisting of 218 osteosarcoma
cases, was also scanned with the OmniExpress SNP microarray (Supplemental Table 1). The
same quality filtering and population substructure analyses were applied, resulting in an
additional 98 cases of European ancestry for the final analysis. The choice of SNPs for
follow-up was generated based on the first set (Stage 1A) but for the final analysis, we
present the results of the full set of 694 cases (namely, the combined Stages 1A and 1B).
Overall, 698,968 SNPs passed quality control metrics for the full set of 694 cases for final
analysis. The number of SNPs overlapping with pooled controls was 510,856, 510,856,
310,384 and 304,092 for the USA, Spain, Italy and UK components, respectively, and were
used in the association analyses (see Online Methods).
We combined already scanned controls drawn from two large cohort studies, Prostate, Lung,
Colon and Ovarian Cancer Prevention Trial [PLCO]15 and the American Cancer Society
Cancer Prevention Study-II [CPSII]16 scanned on Illumina Omni 2.5M array and three
European studies (i.e., Spanish Bladder Cancer Study17 on the HumanHap 1M SNP
microarray, Environment and Genetics Lung Cancer Etiology Study [EAGLE]18/on the
HumanHap 550 SNP microarray and the Wellcome Trust Case Control Consortium
[WTCCC]19 with the HumanHap 550 SNP microarray). We selected 2,703 controls based
on comparable quality control metrics for comparison with the scanned cases. A systematic
assessment of the underlying population substructure was conducted as described above to
remove highly admixed individuals (non-European admixture of >20%) from a model to
investigate cases of European background (Supplementary Figures 2 and 3).
Association analyses were performed using a 1-degree of freedom trend test adjusted by sex
and eigenvectors. Optimized TaqMan assays were designed based on SNP associations
observed in the first set of cases in the scan, known as Stage 1A (Supplementary Table 2).
This set of 30 SNPs was genotyped in a follow-up set of 247 osteosarcoma cases
(Supplemental Table 1) and 588 controls drawn from PLCO and NHS. A fixed effect meta-
analysis was applied to the combined results of the two scanned sets comprising Stage 1
(596 cases in Stage 1A and 98 cases in Stage 1B yielding a total of 694 total, unique cases)
with the replication stage of 30 SNPs with P <1.0 × 10-4.
In a fixed effect meta-analysis of all cases and controls of European ancestry, 941 cases and
3,291 cancer-free adult controls, we observed two regions that achieved genome-wide
significance on chromosomes 6p21.3 and 2p25.2 (Table 1 and Supplementary Table 2).
The locus on 6p21.3, marked by rs1906953 is associated with susceptibility to osteosarcoma
(P=8.0×10-9, odds ratio (OR) 1.57, 95% confidence interval (CI) 1.35-1.83) (Table 1). The
SNP, rs1906953, is located in intron 7 (IVS 7-32066 C>T) of the glutamate receptor
metabotropic 4 (GRM4) gene (Figure 1A). Our most significant SNP resides within the
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gene, GRM4, which is within a distinct haplotype block from the HLA Class II region, which
is more than 1Mb telomeric on 6p21.3. It is also notable that between the HLA Class II
region and our signal for OS is a distinct region containing BAK1, which in published
GWAS studies has been conclusively associated with platelet counts20-22, chronic
lymphocytic leukemia23, and testicular germ cell tumors24.
The reference allele (C) of GRM4 is highly conserved and its allele frequency is higher in
more ancient populations; the global minor allele frequency (MAF) is 0.29 in the 1000
Genomes Project (Phase 1 genotype data from 1094 individuals25) data, with a greater
frequency in individuals of Asian or African ancestry (MAF 0.46 and 0.59, respectively).
While there are four surrogates in individuals of European background (r2>0.6 and within
±500kb) in the 1000 Genomes data, the index SNP, rs1906953, maps to a DNaseI
hypersensitivity region in the Encyclopedia of DNA Elements (ENCODE)26 data set, raising
the distinct possibility that the variant is within a region that is accessible to open chromatin
(Supplementary Table 3) and could manifest active regulatory elements. One intronic
surrogate SNP (rs73410895) is predicted to alter known regulatory motifs (Supplementary
Table 3).
GRM4 is a plausible candidate gene that has been implicated in intracellular signaling and
inhibition of the cyclic AMP (cAMP) signaling cascade. In mice, a cAMP-dependent protein
kinase (Prkar1α) is an osteosarcoma tumor suppressor gene involved in tumorigenesis27,28,
suggesting the cAMP pathway is important in osteosarcoma. Although, glutamate signaling
is best characterized in the central nervous system (CNS), where it is known to be involved
in the excitability of gonadotropin releasing hormone neurons, it also occurs in bone29. The
GRM4 receptor is expressed in bone osteoblast (bone-building) and osteoclast (bone-
resorbing) cells, suggesting that glutamate signaling is involved in cell differentiation and
regulation of bone formation and resorption30. GRM4 is expressed in human osteosarcoma
cells31 and associated with poor prognosis in colorectal cancer32, pediatric CNS tumors33,
rhabdomyosarcoma, and multiple myeloma34, as well as cancer cell proliferation in vitro35.
A second signal was observed in an intergenic region on chromosome 2p25.2 (Figure 1B);
rs7591996 (OR 1.39, 95% CI 1.23-1.54, P=1.0 × 10-8) achieved genome-wide significance.
A second SNP, rs10208273, was moderately correlated with the first signal (r2=0.32 in
HapMap 3 release 2) and approached genome-wide significance (OR 1.35, 95% CI
1.21-1.52, P=2.9 × 10-7) (Figure 1B and Table 1). The risk allele frequency for rs7591996 in
our cases of European ancestry was 0.50 and 0.45 for the controls. rs7591996 has a global
MAF of 0.38 in the 1000 Genomes data; the risk allele is the minor allele in CEU
individuals and the major allele in individuals of Asian or African ancestry (MAF 0.35 and
0.14, respectively). Both rs7591996 and rs10208273 occur in a region of relatively low
linkage disequilibrium (Figure 1B). The 1000 Genomes data for European populations
documents at least 27 surrogate SNPs (r2>0.6 and within ±500kb). Based on ENCODE26
data, the two index SNPs do not localize to a region of active regulatory elements or
transcription factor binding sites. However, several of the surrogate SNPs alter known
regulatory motifs and transcription factor binding sites (Supplementary Table 3) and may
affect regulation. These findings suggest that further sequencing and fine-mapping will be
required to determine which variants will be optimal for functional studies needed to explain
the direct association.
Finally, we report a third locus that is promising but does not yet achieve genome-wide
significance, rs17206779, (OR 0.75, 95% CI 0.68 to 0.84, P=5.1×10-7) located in the
ADAM metallopeptidase with thrombospondin type 1 motif, 6 (ADAMTS6) gene (g.
64447777C>T) on chromosome 5q12.3. It is notable that variation in genes encoding
members of the ADAMTS protein family have been associated with height36, a known risk
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factor for osteosarcoma2. Further data are required to confirm this locus, and then fine-map
the region prior to conducting functional studies.
To further explore the two significant regions reported in this manuscript, we imputed SNPs
based on the 1000 Genomes data (March 2012 release) together with the DCEG Imputation
Reference Set version 137 using the IMPUTE2 program38 across a 1 Mb region centered on
each index SNP (see Online Methods). A subsequent association analysis did not identify
new signals that are substantially stronger than the genotyped SNPs for both 2p25.2 and
5q12.3 regions (Supplementary Figure 4). Although there appear to be stronger signals in
the imputed data for the HLA Class II region (Supplementary Figure 4a), there is a strong
recombination hotspot separating it from the region marked by the index SNP rs1906953. In
this regard, it will be critical to pursue more detailed mapping and genotyping of the HLA
class II region to determine if there is an independent signal in addition to that which resides
in the GRM4 gene.
An assessment of loci previously reported in candidate gene association studies3-12 did not
reveal that the reported loci approached genome-wide significance (Supplementary Table 4).
It is notable that the SNPs in the 8q24.3 locus as well as the multi-cancer 8q24.21 region
appear to be promising candidates10; the strongest signal of a set of highly correlated SNPs
on 8q24.21, rs11777807, demonstrated a P= 4.6 × 10-5, and rs369051 on 8q24.3 had a P =
1.16 × 10-4. Further sample sizes are needed to determine if these are stable or perhaps due
to chance.
We have conclusively identified two susceptibility regions, on chromosome 2p25.2 and
6p21.3, the latter harboring a plausible candidate gene, GRM4, in a multistage GWAS of
osteosarcoma. It is noteworthy that the loci we have identified demonstrate estimated odds
ratios greater than 1.5, values greater than those observed for most adult cancer GWAS. Our
findings are consistent with the high risk estimates reported for Ewing's sarcoma13 and
ALL14, other rare pediatric tumors. Further investigation of these associated loci is
warranted to uncover the biological mechanisms underlying susceptibility to osteosarcoma.
Online Methods
Genome-wide SNP Genotyping
Genome-wide SNP genotyping of osteosarcoma cases was conducted using the Illumina
OmniExpress Beadchip at the NCI Cancer Genomics Research Laboratory (CGR) in the
Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute,
Bethesda, USA. Genotype analysis occurred in two stages because of the sequential receipt
of samples. Stage 1A consisted of 910 unique cases from the Children's Oncology Group
(COG), Toronto Study, PamplonaCUN, Rizzoli (Italy), Ankara (Turkey) and University
College London (UCL). Adult, cancer-free controls were drawn from previously scanned
studies in the US (add references), namely, the Prostate, Lung, Colon and Ovary Prevention
Trial (PLCO) and the Cancer Prevention Study-II (CPS-II) of the American Cancer Society,
both scanned on the Omni 2.5 M SNP microarray; European controls were drawn from the
EAGLE (Italy) scanned on the HumanHap550, the Welcome Trust Case-Control Cohort-UK
(WTCCC-UK) scanned on the Human Hap550 and the NCI-Spanish Bladder Cancer Study,
scanned on the Human Hap 1 M SNP microarray chip. Stage 1B consisted of unique 218
cases scanned on the Omni Express Beadchip drawn from UCL, Rizzoli, PamplonaCUN
studies plus two additional studies from the PeterMac (Australia) and Brazil. Cancer-free
adult controls were drawn from the PLCO and the Nurses Health Study (NHS), scanned on
the Illumina 2.5 M Omni and the OmniExpress, respectively.
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Each participating study obtained informed consent from study participants and approval
from its Institutional Review Board (IRB) for this study and obtained IRB certification
permitting data sharing in accordance with the NIH Policy for Sharing of Data Obtained in
NIH Supported or Conducted Genome-Wide Association Studies (GWAS). The CGEMS
data portal provides access to individual level data from the NCI scan ONLY to
investigators from certified scientific institutions after approval of their submitted Data
Access Request.
Quality Control Assessment
Systematic quality control was conducted which included QC steps specific for the
performance of different arrays at distinct times. For SNP assays, exclusions included those
with less than 90% of completion rate, and SNPs with extreme deviation from fitness for
Hardy-Weinberg proportion (P <1×10-7). There were 29 duplicated cases in Stages 1A and
1B; concordance rates were 99.96%.
Analysis of Stage 1A—In the QC analysis of stage 1A, samples were excluded based on:
1) completion rates lower than 94% (n=28 samples); 2) abnormal heterozygosity values of
less than 20% or greater than 31% (n=8); 3) expected duplicates (n=23 pairs); 4) abnormal
X chromosome heterozygosity (n=1); 5) phenotype exclusions (due to ineligibility or
incomplete information) (n=57). Genotypes for all subject pairs were also computed for
close relationships (1-2nd degree) using GLU qc.ibds module with an IBD0 threshold of
0.70; no first-degree relatives were identified in the cases scanned. Utilizing a set of 12,000
un-linked SNPs (pair-wise r2 <0.004) common to the GWAS chips used herein33, 264
subjects with less than 80% European ancestry were excluded based on STRUCTURE
analysis34 and PCA35; majority of these represent 97 cases of African American ancestry
and 99 of Hispanic ancestry. The final participant count for the association analysis for
Stage 1A was 596 cases and 2,703 controls of European ancestry. 698, 968 SNPs were
available after the QC filtering. The number of SNPs overlapping with pooled controls are
follows, 510,856, 510,856, 310,384 and 304,092 for the USA, Spain, Italy and UK
components, respectively, were used in the downstream association analyses. PCA analyses
per components did not reveal significant differences between cases and controls using the
same 12,000 SNPs described above.
Analysis of Stage 1B—Similar quality control metrics were applied to the second set of
additional scanned cases, known as Stage 1B. For the current analysis, an additional 98
cases were added to the association analysis of individuals of European ancestry.
Quality control metrics for previously scanned cancer-free adult controls—
The pooled PLCO controls were scanned on the Illumina Human Omni2.5 array, we
excluded samples with missing rate > 6%; excluded SNPs with missing rate > 10%;
excluded samples with mean heterozygosity > 21% or < 16%; excluded one from each of
cryptic related pair; excluded non-CEU admixed individuals based on the STRUCTURE
analysis. The pooled SPBC controls were scanned on Illumina 1M SNP array and the
genotype QC were previously described17; the pooled EAGLE controls were scanned on
Illumina 550K SNP array and the genotype QC were previously published18; the pooled
WTCCC controls were previously described39.
Replication and TaqMan genotyping
A follow-up analysis of the 30 SNPs selected for replication (based on Stage 1A) was
conducted using the TaqMan genotyping assays (ABI, Foster City, CA) that were optimized
in the CGR pipeline. A total of 247 cases and 550 controls were analyzed; the studies
included 99 histologically confirmed osteosarcoma cases and 65 hospital-based cancer-free
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pediatric controls from the National Osteosarcoma Etiology Study Group plus 148 cases
drawn from the studies used in the scan in which there was insufficient DNA for scanning.
Cancer-free controls were also selected from the PLCO and NHS studies (previously
analyzed on the Omni2.5M and OmniExpress, respectively).
Statistical analysis
Associations between the SNPs and the risk of osteosarcoma were estimated using
unconditional logistic regression by the odds ratio (OR) and 95% confidence interval (CI)
using the multivariate unconditional logistic regression assuming a trend genetic model (the
effect of the variant by log-additive model with 1 degree of freedom). PCA analysis revealed
four significant (p<0.05) eigenvectors when included in the NULL model. The main effect
model was adjusted by sex, country, four eigenvectors, based on significance with p<0.05
observed in the NULL model. For the replication studies, the analysis was adjusted for sex
only.
For stage 1 (A + B), in addition to the joint analysis detailed as above, a fixed effect meta-
analysis was performed to combine results for each country (component) to facilitate
filtering out artifacts by checking for the heterogeneity across countries. Similar meta-
analysis was also performed to combine scan (discovery) association results with taqman
(replication) association results for those 30 SNPs.
The estimated inflation factors, λ and adjusted λ1000 of the test statistic for the combined
Stage 1A and 1B were 1.036 and 1.033.
Recombination hotspots were identified in the vicinity of osteosarcoma associated loci on
6p21.31 and 2p25.2 using SequenceLDhot40, a program that uses approximate marginal
likelihood method41 and calculates likelihood ratio statistics at a set of possible hotspots. We
tested 5 unique sets of 100 control samples drawn from controls. PHASE v2.1 program was
used to calculate background recombination rates42,43 and LD heatmap was visualized in r2
using snp.plotter program44.
Imputation
In order to further interrogate the loci associated with osteosarcoma, we imputed additional
SNPs within 1 Mb on either side of the implicated SNPs using IMPUTE2 software and the
reference data from both the 1000 Genomes project13 and the DCEG Imputation Reference
Set version 137. SNPTEST was used to analyze the posterior SNP dosages from IMPUTE2,
adjusting for sex, country, and four eigenvectors, as described above45.
Data Analysis
Data analysis and management was performed with GLU (Genotyping Library and Utilities
version 1.0), PLINK, Eigenstrat, IMPUTE2, and SNPTEST.
URLs
CGEMS portal: http://cgems.cancer.gov/
CGF: http://cgf.nci.nih.gov/
GLU: http://code.google.com/p/glu-genetics/
EIGENSTRAT: http://genepath.med.harvard.edu/∼reich/EIGENSTRAT.htm
STRUCTURE: http://pritch.bsd.uchicago.edu/structure.html
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PLINK: http://pngu.mgh.harvard.edu/∼purcell/plink/
SequenceLDhot: http://www.maths.lancs.ac.uk/∼fearnhea/Hotspot/
snp.plotter: http://cbdb.nimh.nih.gov/∼kristin/snp.plotter.html
PHASE v2.1: http://www.stat.washington.edu/stephens/phase/download.html
IMPUTE2: http://mathgen.stats.ox.ac.uk/impute/impute_v2.html
SNPTEST: https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regional plots of loci associated with osteosarcoma
Regional plots of association results, recombination hotspots and linkage disequilibrium for
the (a) 6p21.31:34,046,381–34,243,213 and (b) 2p25.2:6,280,533–6,473,384 osteosarcoma
susceptibility loci. Association results from a trend test in –log10P values (y axis, left; gray
diamonds, combined GWAS result; sky blue diamonds, TaqMan result; red diamonds,
combined result) of the SNPs are shown according to their chromosomal positions (x axis).
Linkage disequilibrium structure based on controls (n=2,703) was visualized by snp.plotter
software. The line graph shows likelihood ratio statistics (y axis, right) for recombination
hotspot by SequenceLDhot software and 5 different colors represent 5 tests of 100 controls
without resampling. Physical locations are based on NCBI human genome build 36. Gene
annotation was based on the NCBI RefSeq genes from the UCSC Genome Browser.
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